Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 15/20 | 0.54 |
| ▸ | NPC1 | O15118 | 14/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 6/20 | 0.54 |
| ▸ | GFER | P55789 | 2/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30714904 | 1.00 | RAB9A (0.54) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4627970 | 0.93 | RAB9A (0.51) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL18807110 | 0.82 | RAB9A (0.60) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL31731985 | 0.81 | RAB9A (0.67) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL30714867 | 0.81 | RAB9A (0.62) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL10978758 | 0.81 | RAB9A (0.62) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL18807101 | 0.80 | SUV39H2 (0.46) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4790656 | 0.79 | RAB9A (0.54) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL30558267 | 0.79 | RAB9A (0.61) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL10333641 | 0.79 | RAB9A (0.61) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787448-B2 | Indolizino [3,2-C] quinoline-based fluorescent probe | SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION (KR) | 2020-09-29 | — | — | US | disclosed |
| US-10454043-B2 | Heterocyclic compound and organic light-emitting element using same | HEESUNG MATERIAL LTD. (KR) | 2019-10-22 | — | — | US | disclosed |
| EP-3165527-B1 | COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | SAMSUNG DISPLAY CO LTD (KR) | 2019-06-26 | — | — | EP | disclosed |
| US-20170324046-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT USING SAME | HEESUNG MATERIAL LTD. (KR) | 2017-11-09 | — | — | US | disclosed |
| US-20170324046-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT USING SAME | HEESUNG MATERIAL LTD. (KR) | 2017-11-09 | — | — | US | disclosed |
| EP-3214085-A2 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT USING SAME | Heesung Material Ltd. (KR) | 2017-09-06 | — | — | EP | disclosed |
| EP-3165527-A1 | COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | Samsung Display Co., Ltd. (KR) | 2017-05-10 | — | — | EP | disclosed |
| US-20170125696-A1 | COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-05-04 | — | — | US | disclosed |
| US-20170125696-A1 | COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-05-04 | — | — | US | disclosed |
| US-9331290-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2016-05-03 | — | — | US | disclosed |
| WO-2007019346-A1 | BENZOTHIAZOLES AND THIAZOLOPYRIDINES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019346-A1 | BENZOTHIAZOLES AND THIAZOLOPYRIDINES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019344-A1 | IMIDAZO [2,1-B] THIAYOLE DERIVATIVES AS SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019344-A1 | IMIDAZO [2,1-B] THIAYOLE DERIVATIVES AS SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2007019417-A1 | OXAZOLOPYRIDINE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019416-A1 | BENZIMIDAZOLE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019417-A1 | OXAZOLOPYRIDINE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10454043-B2 | Heterocyclic compound and organic light-emitting element using same | CRY1, CRY2, PER2 | RAB9A 3098/4885NPC1 4160/4885KDM4E 1752/4885 |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRT1, SIRT3, SIRT2 | RAB9A 1526/4885NPC1 2905/4885KDM4E 540/4885 |
| US-10787448-B2 | Indolizino [3,2-C] quinoline-based fluorescent probe | DNA2, IRF3, DDB1 | RAB9A 3363/4885NPC1 1024/4885KDM4E 4624/4885 |
| US-20170125696-A1 | COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | VDAC1, VDAC2, MCOLN2 | RAB9A 2254/4885NPC1 836/4885KDM4E 2677/4885 |
| US-20170324046-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT USING SAME | CRY1, CRY2, PER2 | RAB9A 3098/4885NPC1 4160/4885KDM4E 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.